Lactose to Treat Acute and Chronic Portal Systemic Encephalopathy
The therapeutic effect of the semi-synthetic disaccharide lactulose, in the management of patients with acute and chronic portal systemic encephalopathy (PSE) has been demonstrated in controlled trials.1, 2 However, in developing countries the high cost and unavailability of lactulose constitute a serious drawback. In the majority of developing countries there is a high prevalence of primary lactase malabsorption. Lactose malabsorption ranges from 6% in predominant Caucasian populations to 90–95% in countries with predominantly oriental or black population.3 In Mexico 74% of the people is lactase deficient.
KeywordsHepatic Encephalopathy Lactase Deficiency Blood Ammonia Placebo Tablet Lactose Malabsorption
Unable to display preview. Download preview PDF.
- 3.T. Gilat, Lactase deficiency: the world pattern today, Israel J. Med. Sci. 15: 369 (1979).Google Scholar
- 4.H. Lewis, S. Rojas, and M. Uribe, Similar effect of lactose and lactulose on in vitro fecal ammonia generation and bacterial flora. (Abstr.) Gastroenterology 78: 1206 (1980).Google Scholar
- 6.J. M. Bond and M. D. Levitt, Investigation of small transite time utilizing pulmonary hydrogen (H2) measurements, J. Lab. Clin. Med. 85: 546 (1979).Google Scholar
- 8.M. Uribe and H. O. Conn, Effect of antacids on intestinal response and stool acidification induced by lactose and lactulose in lactose intolerant subjects, Gastroenterology 82: 1248 (1982).Google Scholar